Skip to main content
. 2022 Apr 18;11(4):e1388. doi: 10.1002/cti2.1388

Figure 2.

Figure 2

Binding and pseudo‐neutralising antibody titres over time following BNT162b2 and ChAdOx1 nCoV‐19 vaccination with and without prior SARS‐CoV‐2 infection. (a) Binding antibody titres against SARS‐CoV‐2 wild type over 7 months following the second BNT162b2 dose (n = 335) and 3 months following the second ChAdOx1 nCoV‐19 dose (n = 107) in SARS‐CoV‐2‐recovered and SARS‐CoV‐2‐naïve vaccinees, (b) pseudo‐neutralising antibodies against the wild type over 7 months following the second BNT162b2 dose (n = 312) and 3 months following the second ChAdOx1 nCoV‐19 dose (n = 100) in SARS‐CoV‐2‐recovered and SARS‐CoV‐2‐naïve vaccinees, and (c) pseudo‐neutralising antibodies against the Delta variant type over 7 months following the second BNT162b2 dose (n = 312) and 3 months following the second ChAdOx1 nCoV‐19 dose (n = 100) in SARS‐CoV‐2‐recovered and SARS‐CoV‐2‐naïve vaccinees. Dots and crosses represent GMTs, and bars represent 95% CI. Solid lines represent SARS‐CoV‐2‐recovered vaccinees, and dotted lines represent SARS‐CoV‐2‐naïve vaccinees. WT, wild type; BAU, binding antibody units; AU, arbitrary units.